Life Science Vacancy 2026: Boston, Bay Area and San Diego Labs Average 26.8%
Life science vacancy in 2026 reached 28.1% in Greater Boston, 23.8% in the Bay Area and 28.5% in San Diego in the third quarter, Savills data reported October 20, 2026 show.
Those three hubs hold most of the country's lab space, and none of them is close to a healthy vacancy rate. Venture capital, the money that fills lab buildings, also fell from a year earlier in all three markets, according to Commercial Observer.
By the Numbers
- Greater Boston lab vacancy was 28.1% in the third quarter of 2026, with 3.2 million square feet still under construction, according to Commercial Observer, citing Savills.
- San Diego vacancy rose 60 basis points from a year earlier to 28.5%, the highest of the three hubs, per Commercial Observer.
- Bay Area life science companies raised $8.3 billion across 428 deals in the first nine months of 2026, down 13.3% from 2025, per Commercial Observer.
- Seattle lab vacancy rose 150 basis points to 18.9% in the third quarter, according to Savills data reported by The Registry.
- About 55.6% of the nearly 60 million square feet of lab space delivered from 2020 through 2025 was vacant as of February 2026, according to a Savills research spotlight.
Life Science Vacancy 2026: What Happened in the Third Quarter
Savills published its third quarter 2026 life sciences market reports in October, and Commercial Observer summarized the three largest hubs on October 20, 2026. Vacancy ranged from about 24% to just over 28%. The Bay Area was the only one of the three to post a small yearly improvement.
Funding was weaker across the board. Each hub raised less venture capital in the third quarter of 2026 than in the same quarter of 2025. That matters because most lab tenants are young biotech firms that lease space only after they raise money.
Greater Boston: The Largest Lab Market Carries the Most Space
Greater Boston is the biggest of the three markets, with 44.4 million square feet of lab inventory, per Commercial Observer. Vacancy reached 28.1% in the third quarter. Another 3.2 million square feet is under construction, which means more space will arrive before the glut clears.
Venture funding in the region totaled $2.7 billion in the third quarter, down from $3.2 billion a year earlier. National Institutes of Health (NIH) funding, the federal research grants many labs depend on, fell by about $200 million from 2025. Boston still received more NIH money than the Bay Area or San Diego.
Other trackers see similar stress. CBRE put Greater Boston lab vacancy at 28.9% in the third quarter, with asking rents down 8.1% from a year earlier to $77.97 per square foot on a triple net basis. Brokers measure markets differently, so readers should compare each firm's figures only with its own past reports.
There were large deals. Sanofi signed two of the market's biggest leases, 500,000 square feet at 350 Water Street and 400,000 square feet at 450 Water Street in Cambridge, per Commercial Observer. Genentech opened a 95,000 square foot center on a 10-year lease at Harvard's Enterprise Research Campus in Allston.
Gillette bought 232 A Street in the Seaport for about $99.3 million to build its headquarters. The seller, a Tishman Speyer and Bellco Capital venture, paid $80 million for the site in 2021, according to CRE Daily. The site had approval for a 325,000 square foot research campus, so a planned lab project became a corporate headquarters.
Bay Area: Lower Vacancy and a Shrinking Pipeline
The Bay Area posted the lowest vacancy of the three hubs at 23.8%, down 20 basis points from a year earlier, per Commercial Observer. Inventory grew slightly to 37.2 million square feet. Only 800,000 square feet was under construction, down from 1.4 million a year earlier.
The quarter's biggest deal was Revolution Medicines, which signed for 672,000 square feet at Pacific Shores Center in Redwood City. The campus was formerly a Google hub, and Connect CRE reported in August 2026 that the drug developer was nearing a deal of about 700,000 square feet there.
Roche and Intuitive Surgical also signed smaller leases in San Jose and Sunnyvale, per Commercial Observer.
Funding remains the soft spot. Bay Area companies raised $2.6 billion in the third quarter, compared with $4.8 billion in the third quarter of 2025. A Morabito Investment Group calculation puts that drop at about 46%.
San Diego: Highest Vacancy as Construction Stops
San Diego had the highest vacancy of the three at 28.5%, up 60 basis points from a year earlier, per Commercial Observer. Inventory grew from 27.3 million to 27.8 million square feet. Almost nothing is now under construction, compared with 600,000 square feet a year earlier.
The region saw the steepest funding decline. Life science companies raised $1.4 billion through September, down 34.1% and the lowest nine-month total since 2022. Third quarter funding was $500 million, compared with $900 million a year earlier.
Alexandria Real Estate Equities completed a 427,000 square foot research building for Bristol Myers Squibb at its 2.9 million square foot Campus Point campus. Capricor Therapeutics signed for 171,001 square feet at 9625 Towne Centre Drive. Aspen Neuroscience and Exagen also signed leases in Torrey Pines and Carlsbad.
Lab Space Vacancy Across the Three Hubs: A Combined View
The three markets average 26.8% vacancy on a simple, unweighted basis, according to a Morabito Investment Group analysis of Savills figures reported by Commercial Observer. Weighted by each market's inventory, the average is about 26.7%. Together the hubs hold 109.4 million square feet of lab space.
Multiplying each vacancy rate by its inventory implies roughly 29.3 million square feet of empty lab space across the three hubs. That is an estimate, since vacancy and inventory may be measured on slightly different bases. Still, it gives a sense of how much demand the market needs to absorb.
Third quarter venture funding in the three hubs totaled $5.8 billion, down from $8.9 billion a year earlier, according to the same Morabito Investment Group analysis. That is a decline of about 34.8%. Combined construction in Boston and the Bay Area totals about 4.0 million square feet, with San Diego adding almost nothing.
Why Life Science Real Estate Is Still Oversupplied
The glut traces back to a pandemic building boom. Nearly 60 million square feet of lab space was delivered across 11 U.S. hubs from 2020 through 2025, according to the Savills research spotlight. Annual deliveries climbed from about 4.5 million square feet in 2020 to 14.5 million in 2025.
Much of that space never found tenants. Savills found that 73.4% of space delivered in 2025 was vacant as of February 2026. Since 2023, 34 life science buildings were completed without signing a single tenant, according to Commercial Property Executive.
Converting labs to other uses is hard. Savills research manager Brianna Friedman told Commercial Property Executive in April 2026 that conversion is often not economical because of specialized systems such as heavy ventilation and deep floor plates. That leaves owners competing on price and concessions instead.
Implications for Investors, Owners and Developers
Lab vacancy in the high 20s now exceeds the office sector, where national vacancy was 19.8% in the third quarter, as covered in our report on office vacancy rates in Q3 2026. Unlike office, though, the lab pipeline is collapsing quickly. San Diego has almost no new supply, and Bay Area construction fell about 43% in a year.
- Tenants have leverage. Landlords are offering free rent, larger tenant improvement (TI) allowances, which pay for a tenant's build-out, and flexible lease terms, according to Savills findings reported by Commercial Property Executive.
- Pricing has reset for some assets. Discounted lab buildings may appeal to buyers with patient capital, though the timing of a recovery depends on funding that no one can forecast with confidence.
- Quality is splitting the market. The largest leases went to newer, well-located buildings, a pattern similar to the flight to top-tier space seen in the U.S. office market in 2026.
- Valuations are still under pressure. Broader commercial property prices have stalled, as covered in our report on commercial real estate prices, and lab assets with high vacancy face the same lender caution.
For more on how MIG views office, lab and other commercial property types, see our commercial real estate sector page.
What to Watch
- Fourth quarter 2026 venture capital totals in Boston, the Bay Area and San Diego, since funding drives lab leasing.
- NIH grant levels for 2027, which support university and nonprofit research tenants.
- Whether the 3.2 million square feet under construction in Greater Boston is preleased or arrives empty.
- Sales of lab buildings at discounts, which would set new pricing for the sector.
Frequently Asked Questions
What is the Boston lab space vacancy rate?
Savills put Greater Boston life science vacancy at 28.1% in the third quarter of 2026, per Commercial Observer. CBRE measured 28.9% for the same quarter, according to CBRE. The gap reflects different market definitions.
What is the life science real estate market outlook?
Savills has said high vacancy does not undermine the sector's long-term strength, pointing to growth in gene editing, cell therapy and AI drug discovery, per Commercial Property Executive. In the near term, falling construction and weaker funding pull in opposite directions. Recovery depends on venture capital returning.
Which life science market has the highest vacancy?
Among the three largest hubs, San Diego had the highest vacancy at 28.5% in the third quarter of 2026, per Commercial Observer. Greater Boston followed at 28.1%, and the Bay Area was lowest at 23.8%.
Key Takeaways
- Lab vacancy in Boston, the Bay Area and San Diego averages 26.8% on an unweighted basis, according to a Morabito Investment Group analysis of Savills data.
- Third quarter 2026 venture funding across the three hubs fell about 34.8% from a year earlier, to $5.8 billion.
- New lab construction has nearly stopped in San Diego and fallen sharply in the Bay Area, which limits future supply.
Bottom Line
Life science vacancy in 2026 remains near record levels in the three largest U.S. hubs, and funding is still slipping. The shrinking construction pipeline is the main sign that the oversupply will eventually work itself out. For investors, the key signal to track is venture capital, because lab demand follows the money.
Image credit: Photo by Trnava University on Unsplash.
Sources
- Commercial Observer, "Life Sciences Vacancy Near 27% for Three Biggest U.S. Hubs," https://commercialobserver.com/2026/10/life-sciences-vacancy-boston-bay-area-san-diego/
- The Registry, "Seattle Life Science VC Plunges 58% to $396MM as Bay Area Funding Holds at $8.3B," https://news.theregistryps.com/seattle-life-science-vc-plunges-58-to-396mm-as-bay-area-funding-holds-at-8-3b/
- Savills Research, "The Great Lab Space Boom: Excess Vacancy Sets the Stage for the Next Cycle," https://pdf.euro.savills.co.uk/usa/life-sciences/final-savills-ls-spotlight-march2026.pdf
- Commercial Property Executive, "Life Science Sector Faces Vacancy Glut After Construction Boom," https://www.commercialsearch.com/news/life-science-sector-faces-excess-vacancy-after-construction-boom/
- CBRE, "Boston Metro Life Science Figures Q3 2026," https://www.cbre.com/insights/figures/boston-metro-life-science-figures-q3-2026
- CRE Daily, "Gillette Buys South Boston Life Science Site for $99.29M," https://www.credaily.com/briefs/gillette-buys-south-boston-life-science-site-for-99-29m/
- Connect CRE, "Biotech Firm Nears 700K-SF Lease at Former Google Hub," https://www.connectcre.com/stories/biotech-firm-nears-700k-sf-lease-at-former-google-hub/
Disclaimer: This article is for general information and education only. It is not investment, financial, legal, tax or accounting advice, and it is not an offer or solicitation to buy or sell any security or property. Morabito Investment Group does not guarantee that the information is complete, accurate or current. Figures, forecasts and opinions from third parties belong to their sources. All investments carry risk, including loss of principal, and past results do not guarantee future results. Do your own research and consult a licensed professional before making any investment, financing or other decision. You use this information at your own risk.
This article is for general information only. It is not legal, tax, financial, or investment advice, and it is not an offer to sell or a solicitation of an offer to buy any security. Talk to your own advisors before acting on anything in it. Views are current as of the publish date and may change without notice.








